BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, Canenguez K, Park JK, Kelly E, Jacobson E, Kerr CE, Lembo AJ. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005;17:332-40. [PMID: 15916620 DOI: 10.1111/j.1365-2982.2005.00650.x] [Cited by in Crossref: 211] [Cited by in F6Publishing: 217] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Ongaro G, Ballou S, Kube T, Haas J, Kaptchuk TJ. Doctors Speak: A Qualitative Study of Physicians' Prescribing of Antidepressants in Functional Bowel Disorders. Cult Med Psychiatry 2022. [PMID: 35764862 DOI: 10.1007/s11013-022-09795-0] [Reference Citation Analysis]
2 Rijnaarts I, de Roos NM, Wang T, Zoetendal EG, Top J, Timmer M, Hogenelst K, Bouwman EP, Witteman B, de Wit N. A high-fibre personalised dietary advice given via a web tool reduces constipation complaints in adults. J Nutr Sci 2022;11:e31. [PMID: 35573462 DOI: 10.1017/jns.2022.27] [Reference Citation Analysis]
3 Barberio B, Savarino EV, Black CJ, Ford AC. Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. Clin Gastroenterol Hepatol 2022;20:e923-44. [PMID: 34425274 DOI: 10.1016/j.cgh.2021.08.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
4 De Palma G, Bercik P. Long-term personalized low FODMAP diet in IBS. Neurogastroenterol Motil 2022;34:e14356. [PMID: 35293089 DOI: 10.1111/nmo.14356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Seetharaman J, Poddar U, Yachha SK, Srivastava A, Sen Sarma M. Efficacy of amitriptyline in pediatric functional abdominal pain disorders: A randomized placebo-controlled trial. J Gastroenterol Hepatol 2022;37:685-91. [PMID: 34935191 DOI: 10.1111/jgh.15765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Vollert J, Wang R, Regis S, Yetman H, Lembo AJ, Kaptchuk TJ, Cheng V, Nee J, Iturrino J, Loscalzo J, Hall KT, Silvester JA. Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome. Front Psychiatry 2022;13:842030. [DOI: 10.3389/fpsyt.2022.842030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bao C, Wu L, Shi Y, Shi Z, Jin X, Shen J, Li J, Hu Z, Chen J, Zeng X, Zhang W, Ma Z, Weng Z, Li J, Liu H, Wu H. Long-term effect of moxibustion on irritable bowel syndrome with diarrhea: a randomized clinical trial. Therap Adv Gastroenterol 2022;15:175628482210751. [DOI: 10.1177/17562848221075131] [Reference Citation Analysis]
8 Hunt MG, Dalvie A, Ipek S, Wasman B. Acceptability and efficacy of the Zemedy app versus a relaxation training and meditation app for IBS: protocol for a randomised controlled trial. BMJ Open 2022;12:e055014. [PMID: 35039299 DOI: 10.1136/bmjopen-2021-055014] [Reference Citation Analysis]
9 Nee J, Ballou S, Kelley JM, Kaptchuk TJ, Hirsch W, Katon J, Cheng V, Rangan V, Lembo A, Iturrino J. Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial. Am J Gastroenterol 2021;116:2279-85. [PMID: 34319275 DOI: 10.14309/ajg.0000000000001395] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
10 Pesce M, Puoti MG, Rybak A, Andreozzi M, Bruzzese E, Sarnelli G, Borrelli O. Pharmacological interventions for pediatric irritable bowel syndrome. Expert Opin Pharmacother 2021;:1-13. [PMID: 34523358 DOI: 10.1080/14656566.2021.1976753] [Reference Citation Analysis]
11 Jeitler M, Wottke T, Schumann D, Puerto Valencia LM, Michalsen A, Steckhan N, Mittwede M, Stapelfeldt E, Koppold-Liebscher D, Cramer H, Wischnewsky M, Murthy V, Kessler CS. Ayurvedic vs. Conventional Nutritional Therapy Including Low-FODMAP Diet for Patients With Irritable Bowel Syndrome-A Randomized Controlled Trial. Front Med (Lausanne) 2021;8:622029. [PMID: 34552937 DOI: 10.3389/fmed.2021.622029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Madsen AMA, Halkjær SI, Christensen AH, Günther S, Browne PD, Kallemose T, Hansen LH, Petersen AM. The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study. Scand J Gastroenterol 2021;56:761-9. [PMID: 34000958 DOI: 10.1080/00365521.2021.1915375] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
13 Hunt M, Miguez S, Dukas B, Onwude O, White S. Efficacy of Zemedy, a Mobile Digital Therapeutic for the Self-management of Irritable Bowel Syndrome: Crossover Randomized Controlled Trial. JMIR Mhealth Uhealth 2021;9:e26152. [PMID: 33872182 DOI: 10.2196/26152] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
14 Kang S, Park MY, Brooks I, Lee J, Kim SH, Kim JY, Oh B, Kim JW, Kwon O. Spore-forming Bacillus coagulans SNZ 1969 improved intestinal motility and constipation perception mediated by microbial alterations in healthy adults with mild intermittent constipation: A randomized controlled trial. Food Res Int 2021;146:110428. [PMID: 34119240 DOI: 10.1016/j.foodres.2021.110428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
15 Bosman M, Elsenbruch S, Corsetti M, Tack J, Simrén M, Winkens B, Boumans T, Masclee A, Keszthelyi D. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:459-73. [PMID: 33765447 DOI: 10.1016/S2468-1253(21)00023-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
16 Annoni M, Buergler S, Stewart-Ferrer S, Blease C. Placebo Studies and Patient Care: Where Are the Nurses? Front Psychiatry 2021;12:591913. [PMID: 33790812 DOI: 10.3389/fpsyt.2021.591913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Remes-Troche JM, Taboada-Liceaga H, Gill S, Amieva-Balmori M, Rossi M, Hernández-Ramírez G, García-Mazcorro JF, Whelan K. Nopal fiber (Opuntia ficus-indica) improves symptoms in irritable bowel syndrome in the short term: a randomized controlled trial. Neurogastroenterol Motil 2021;33:e13986. [PMID: 32935904 DOI: 10.1111/nmo.13986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Li X, Li B, Zhang J, Chen T, Wu H, Shi X, Ma J, Qin J, Tang X, Wang F. Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24361. [PMID: 33530231 DOI: 10.1097/MD.0000000000024361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Morishita D, Tomita T, Mori S, Kimura T, Oshima T, Fukui H, Miwa H. Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial. Am J Gastroenterol 2021;116:152-61. [PMID: 32969946 DOI: 10.14309/ajg.0000000000000942] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
20 Staller K, Barshop K, Vélez C, Bailey A, Locascio JJ, Chiquette E, Kuo B. CSP01, a Novel Superabsorbent Hydrogel, Reduces Colonic Transit Time in Patients With Chronic Idiopathic Constipation in a Randomized, Double-blind, Controlled Pilot Clinical Trial. J Neurogastroenterol Motil 2020;26:496-504. [PMID: 32807749 DOI: 10.5056/jnm20001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Fairchild A. The ethical conflict of truth, hope, and the experience of suffering: A discussion of non-disclosure of terminal illness and clinical placebos. Clinical Ethics 2020. [DOI: 10.1177/1477750920959556] [Reference Citation Analysis]
22 Vollert J, Cook NR, Kaptchuk TJ, Sehra ST, Tobias DK, Hall KT. Assessment of Placebo Response in Objective and Subjective Outcome Measures in Rheumatoid Arthritis Clinical Trials. JAMA Netw Open 2020;3:e2013196. [PMID: 32936297 DOI: 10.1001/jamanetworkopen.2020.13196] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
23 Enck P, Klosterhalfen S. Placebo Responses and Placebo Effects in Functional Gastrointestinal Disorders. Front Psychiatry 2020;11:797. [PMID: 33192627 DOI: 10.3389/fpsyt.2020.00797] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
24 Clevers E, Nordqvist A, Törnblom H, Tack J, Masclee A, Keszthelyi D, Van Oudenhove L, Simrén M. Food-symptom diaries can generate personalized lifestyle advice for managing gastrointestinal symptoms: A pilot study. Neurogastroenterol Motil 2020;32:e13820. [PMID: 32031756 DOI: 10.1111/nmo.13820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Kaptchuk TJ, Hemond CC, Miller FG. Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice. BMJ 2020;370:m1668. [PMID: 32690477 DOI: 10.1136/bmj.m1668] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 15.7] [Reference Citation Analysis]
26 Pazhouh HK, Hosseini SMA, Taghipour A, Hamedi S, Noras M. Anti-irritable Bowel Syndrome Syrup Improves Constipation-Predominant Irritable Bowel Syndrome: A Randomized, Placebo-Controlled Trial. Chin J Integr Med 2020;26:729-35. [PMID: 32623701 DOI: 10.1007/s11655-020-3267-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Jean-michel M, Olivier P, Souad R S, Stéphane S. Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome. Results from the LAPIBSS trial: Future objectives. Arch Clin Gastroenterol 2020;6:031-035. [DOI: 10.17352/2455-2283.000075] [Reference Citation Analysis]
28 Lewis ED, Antony JM, Crowley DC, Piano A, Bhardwaj R, Tompkins TA, Evans M. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study. Nutrients 2020;12:E1159. [PMID: 32326347 DOI: 10.3390/nu12041159] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
29 Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol 2020;5:658-66. [PMID: 32277872 DOI: 10.1016/S2468-1253(20)30056-X] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 16.3] [Reference Citation Analysis]
30 Lembo AJ, Covington PS, Dove LS, Andrae DA. Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials. Neurogastroenterol Motil 2020;32:e13774. [PMID: 31984655 DOI: 10.1111/nmo.13774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ratnapalan M, Coghlan B, Tan M, Everitt H, Geraghty AWA, Little P, Lewith G, Bishop FL. Placebos in primary care? a nominal group study explicating UK GP and patient views of six theoretically plausible models of placebo practice. BMJ Open 2020;10:e032524. [PMID: 32075826 DOI: 10.1136/bmjopen-2019-032524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Shin SY, Cha BK, Kim WS, Park JY, Kim JW, Choi CH. The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial. J Neurogastroenterol Motil 2020;26:117-27. [PMID: 31917916 DOI: 10.5056/jnm19160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
33 Johnsen PH, Hilpüsch F, Valle PC, Goll R. The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: Secondary endpoints of a double blind, randomized, placebo-controlled trial. EBioMedicine 2020;51:102562. [PMID: 31877418 DOI: 10.1016/j.ebiom.2019.11.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
34 Nee J, Sugarman MA, Ballou S, Katon J, Rangan V, Singh P, Zubiago J, Kaptchuk TJ, Lembo A. Placebo Response in Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2019;114:1838-46. [PMID: 31592782 DOI: 10.14309/ajg.0000000000000399] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
35 Friesen P. Placebos as a Source of Agency: Evidence and Implications. Front Psychiatry 2019;10:721. [PMID: 31708807 DOI: 10.3389/fpsyt.2019.00721] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Wang RS, Croteau-Chonka DC, Silverman EK, Loscalzo J, Weiss ST, Hall KT. Pharmacogenomics and Placebo Response in a Randomized Clinical Trial in Asthma. Clin Pharmacol Ther 2019;106:1261-7. [PMID: 31557306 DOI: 10.1002/cpt.1646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
37 Martoni CJ, Evans M, Chow CT, Chan LS, Leyer G. Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial. J Dig Dis 2019;20:435-46. [PMID: 31271261 DOI: 10.1111/1751-2980.12797] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
38 Yumizaki T, Maeda M, Fujita T, Kakuyama H, Kumagai Y. A 3-Part Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DSP-6952 in Healthy Japanese Subjects and Those With ≤3 Spontaneous Bowel Movements per Week. Clin Pharmacol Drug Dev 2020;9:353-65. [PMID: 31464087 DOI: 10.1002/cpdd.731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
39 Derakhshande P, Navabi SJ, Shokoohinia Y, Rouhi-Broujeni H, Deris F, Behbood L, Shahbazi F, Amiri M, Farzaei MH. Efficacy and safety of Achillea wilhelmsii C. Koch capsules on symptom severity and quality of life in patients with irritable bowel syndrome: a randomized, placebo-controlled clinical trial. J Complement Integr Med 2019;16:/j/jcim. [PMID: 31442203 DOI: 10.1515/jcim-2018-0123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Zhang L, Liu YX, Wang Z, Wang XQ, Zhang JJ, Jiang RH, Wang XQ, Zhu SW, Wang K, Liu ZJ, Zhu HQ, Duan LP. Clinical characteristic and fecal microbiota responses to probiotic or antidepressant in patients with diarrhea-predominant irritable bowel syndrome with depression comorbidity: a pilot study. Chin Med J (Engl) 2019;132:346-51. [PMID: 30681503 DOI: 10.1097/CM9.0000000000000071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
41 Mutsekwa RN, Larkins V, Canavan R, Ball L, Angus RL. A dietitian-first gastroenterology clinic results in improved symptoms and quality of life in patients referred to a tertiary gastroenterology service. Clin Nutr ESPEN 2019;33:188-94. [PMID: 31451260 DOI: 10.1016/j.clnesp.2019.05.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
42 Friesen P. Mesmer, the placebo effect, and the efficacy paradox: lessons for evidence based medicine and complementary and alternative medicine. Critical Public Health 2019;29:435-47. [DOI: 10.1080/09581596.2019.1597967] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
43 Spantideas N, Drosou E, Bougea A, AlAbdulwahed R. Proton Pump Inhibitors for the Treatment of Laryngopharyngeal Reflux. A Systematic Review. J Voice 2020;34:918-29. [PMID: 31160182 DOI: 10.1016/j.jvoice.2019.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
44 Nasser Y, Petes C, Simmers C, Basso L, Altier C, Gee K, Vanner SJ. Activation of Peripheral Blood CD4+ T-Cells in IBS is not Associated with Gastrointestinal or Psychological Symptoms. Sci Rep 2019;9:3710. [PMID: 30842618 DOI: 10.1038/s41598-019-40124-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
45 Bishop FL, Greville-Harris M, Bostock J, Din A, Graham CA, Lewith G, Liossi C, O'Riordan T, White P, Yardley L. Informing Adults With Back Pain About Placebo Effects: Randomized Controlled Evaluation of a New Website With Potential to Improve Informed Consent in Clinical Research. J Med Internet Res 2019;21:e9955. [PMID: 30664462 DOI: 10.2196/jmir.9955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
46 Browne PD, Nagelkerke SCJ, van Etten-jamaludin FS, Benninga MA, Tabbers MM. Pharmacological treatments for functional nausea and functional dyspepsia in children: a systematic review. Expert Review of Clinical Pharmacology 2018;11:1195-208. [DOI: 10.1080/17512433.2018.1540298] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
47 Antonelli M, Donelli D. Reinterpreting homoeopathy in the light of placebo effects to manage patients who seek homoeopathic care: A systematic review. Health Soc Care Community 2019;27:824-47. [PMID: 30456773 DOI: 10.1111/hsc.12681] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
48 Ballou S, Beath A, Kaptchuk TJ, Hirsch W, Sommers T, Nee J, Iturrino J, Rangan V, Singh P, Jones M, Lembo A. Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation. Clin Gastroenterol Hepatol 2018;16:1738-1744.e1. [PMID: 29654913 DOI: 10.1016/j.cgh.2018.04.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
49 Sagy I, Abres J, Winnick A, Jotkowitz A. Placebos in the era of open-label trials: An update for clinicians. Eur J Clin Invest 2019;49:e13038. [PMID: 30316203 DOI: 10.1111/eci.13038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
50 Smits RM, Veldhuijzen DS, Wulffraat NM, Evers AWM. The role of placebo effects in immune-related conditions: mechanisms and clinical considerations. Expert Review of Clinical Immunology 2018;14:761-70. [DOI: 10.1080/1744666x.2018.1516144] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
51 Brusaferro A, Farinelli E, Zenzeri L, Cozzali R, Esposito S. The Management of Paediatric Functional Abdominal Pain Disorders: Latest Evidence. Paediatr Drugs 2018;20:235-47. [PMID: 29497992 DOI: 10.1007/s40272-018-0287-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
52 Larsen T, Hausken T, Otteraaen Ystad S, Hovdenak N, Mueller B, Lied GA. Does the low FODMAP diet improve symptoms of radiation-induced enteropathy? A pilot study. Scand J Gastroenterol 2018;53:541-8. [PMID: 29113519 DOI: 10.1080/00365521.2017.1397186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
53 Bishop FL, Greville-harris M, Bostock J, Din A, Graham CA, Lewith G, Liossi C, O'riordan T, White P, Yardley L. Informing Adults With Back Pain About Placebo Effects: Randomized Controlled Evaluation of a New Website With Potential to Improve Informed Consent in Clinical Research (Preprint).. [DOI: 10.2196/preprints.9955] [Reference Citation Analysis]
54 Bräscher AK, Witthöft M, Becker S. The Underestimated Significance of Conditioning in Placebo Hypoalgesia and Nocebo Hyperalgesia. Pain Res Manag 2018;2018:6841985. [PMID: 29670678 DOI: 10.1155/2018/6841985] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
55 Blanchard C, Pouchain D, Vanderkam P, Perault-Pochat MC, Boussageon R, Vaillant-Roussel H. Efficacy of phloroglucinol for treatment of abdominal pain: a systematic review of literature and meta-analysis of randomised controlled trials versus placebo. Eur J Clin Pharmacol 2018;74:541-8. [PMID: 29350249 DOI: 10.1007/s00228-018-2416-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
56 Shin SP, Choi YM, Kim WH, Hong SP, Park JM, Kim J, Kwon O, Lee EH, Hahm KB. A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome. J Clin Biochem Nutr 2018;62:179-86. [PMID: 29610559 DOI: 10.3164/jcbn.17-73] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
57 Maragkoudaki M, Chouliaras G, Orel R, Horvath A, Szajewska H, Papadopoulou A. Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain. Acta Paediatr 2017;106:1857-62. [PMID: 28712129 DOI: 10.1111/apa.13992] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
58 Ben-shaanan T, Schiller M, Rolls A. Studying brain-regulation of immunity with optogenetics and chemogenetics; A new experimental platform. Brain, Behavior, and Immunity 2017;65:1-8. [DOI: 10.1016/j.bbi.2016.11.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
59 Ali A, Weiss TR, McKee D, Scherban A, Khan S, Fields MR, Apollo D, Mehal WZ. Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial. BMJ Open Gastroenterol 2017;4:e000164. [PMID: 29018540 DOI: 10.1136/bmjgast-2017-000164] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
60 Bishop FL, Coghlan B, Geraghty AW, Everitt H, Little P, Holmes MM, Seretis D, Lewith G. What techniques might be used to harness placebo effects in non-malignant pain? A literature review and survey to develop a taxonomy. BMJ Open 2017;7:e015516. [PMID: 28667217 DOI: 10.1136/bmjopen-2016-015516] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
61 Halkjær SI, Boolsen AW, Günther S, Christensen AH, Petersen AM. Can fecal microbiota transplantation cure irritable bowel syndrome? World J Gastroenterol 2017; 23(22): 4112-4120 [PMID: 28652664 DOI: 10.3748/wjg.v23.i22.4112] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
62 Wang RS, Hall KT, Giulianini F, Passow D, Kaptchuk TJ, Loscalzo J. Network analysis of the genomic basis of the placebo effect. JCI Insight 2017;2:93911. [PMID: 28570268 DOI: 10.1172/jci.insight.93911] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
63 Krogsgaard LR, Lyngesen M, Bytzer P. Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome. Aliment Pharmacol Ther 2017;45:1506-13. [PMID: 28440580 DOI: 10.1111/apt.14065] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 9.3] [Reference Citation Analysis]
64 Palaniappan M, Heatherly R, Mintz LB, Connelly K, Wimberley T, Balzer AM, Pierini D, Vogel Anderson K. Skills Vs. Pills: Comparative Effectiveness for Low Sexual Desire in Women. Journal of Sex & Marital Therapy 2017;44:1-15. [DOI: 10.1080/0092623x.2017.1305029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
65 Flik CE, Bakker L, Laan W, van Rood YR, Smout AJPM, de Wit NJ. Systematic review: The placebo effect of psychological interventions in the treatment of irritable bowel syndrome. World J Gastroenterol 2017; 23(12): 2223-2233 [PMID: 28405151 DOI: 10.3748/wjg.v23.i12.2223] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
66 Hoekman DR, Zeevenhooven J, van Etten-jamaludin FS, Douwes Dekker I, Benninga MA, Tabbers MM, Vlieger AM. The Placebo Response in Pediatric Abdominal Pain-Related Functional Gastrointestinal Disorders: A Systematic Review and Meta-Analysis. The Journal of Pediatrics 2017;182:155-163.e7. [DOI: 10.1016/j.jpeds.2016.12.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
67 Zheng H, Li Y, Zhang W, Zeng F, Zhou SY, Zheng HB, Zhu WZ, Jing XH, Rong PJ, Tang CZ, Wang FC, Liu ZB, Wang SJ, Zhou MQ, Liu ZS, Zhu B. Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: A randomized controlled trial. Medicine (Baltimore) 2016;95:e3884. [PMID: 27310980 DOI: 10.1097/MD.0000000000003884] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
68 Steinkopf L. The Social Situation of Sickness: an Evolutionary Perspective on Therapeutic Encounters. Evolutionary Psychological Science 2017;3:270-86. [DOI: 10.1007/s40806-017-0086-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
69 Giannetti E, Maglione M, Sciorio E, Coppola V, Miele E, Staiano A. Do Children Just Grow Out of Irritable Bowel Syndrome? J Pediatr. 2017;183:122-126.e1. [PMID: 28108106 DOI: 10.1016/j.jpeds.2016.12.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
70 Clavé P, Tack J. Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis. Therap Adv Gastroenterol 2017;10:311-22. [PMID: 28246548 DOI: 10.1177/1756283X16681708] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
71 Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol 2017; 23(2): 336-344 [PMID: 28127207 DOI: 10.3748/wjg.v23.i2.336] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
72 Giannetti E, Maglione M, Alessandrella A, Strisciuglio C, De Giovanni D, Campanozzi A, Miele E, Staiano A. A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Clin Gastroenterol 2017;51:e5-e10. [PMID: 27306945 DOI: 10.1097/MCG.0000000000000528] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 9.3] [Reference Citation Analysis]
73 Coyne KS, Poon JL, Thompson C, Hu Y, Datto CJ, Sostek M. Translating Clinical Findings into the Patient's Perspective: Post-hoc Pooled Analysis of Bowel Movement Changes as a Predictor of Improvement in Patients' Opioid-induced Constipation Symptoms and Outcomes. Clin Ther 2017;39:75-88. [PMID: 27938897 DOI: 10.1016/j.clinthera.2016.11.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
74 Mosaffa-jahromi M, Lankarani KB, Pasalar M, Afsharypuor S, Tamaddon A. Efficacy and safety of enteric coated capsules of anise oil to treat irritable bowel syndrome. Journal of Ethnopharmacology 2016;194:937-46. [DOI: 10.1016/j.jep.2016.10.083] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
75 Morgen EK, Naugler C. Clinical Action Curves:  Measuring the Magnitude of Physician Response to Abnormal Laboratory Results. Am J Clin Pathol 2016;146:478-86. [PMID: 27686174 DOI: 10.1093/ajcp/aqw132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
76 Abbasnezhad A, Amani R, Hajiani E, Alavinejad P, Cheraghian B, Ghadiri A. Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial. Neurogastroenterol Motil 2016;28:1533-44. [PMID: 27154424 DOI: 10.1111/nmo.12851] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
77 Thomas LV. Probiotics- the journey continues. Int J Dairy Technol 2016;69:469-80. [DOI: 10.1111/1471-0307.12354] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
78 Nanayakkara WS, Skidmore PM, O'Brien L, Wilkinson TJ, Gearry RB. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol. 2016;9:131-142. [PMID: 27382323 DOI: 10.2147/ceg.s86798] [Cited by in Crossref: 31] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
79 McKenzie YA, Bowyer RK, Leach H, Gulia P, Horobin J, O'Sullivan NA, Pettitt C, Reeves LB, Seamark L, Williams M, Thompson J, Lomer MC; (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association). British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet 2016;29:549-75. [PMID: 27272325 DOI: 10.1111/jhn.12385] [Cited by in Crossref: 168] [Cited by in F6Publishing: 180] [Article Influence: 24.0] [Reference Citation Analysis]
80 Hsu HH, Leung WH, Hu GC. Treatment of irritable bowel syndrome with a novel colonic irrigation system: a pilot study. Tech Coloproctol 2016;20:551-7. [PMID: 27194235 DOI: 10.1007/s10151-016-1491-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
81 Turpeinen A, Kautiainen H, Tikkanen M, Sibakov T, Tossavainen O, Myllyluoma E. Mild protein hydrolysation of lactose-free milk further reduces milk-related gastrointestinal symptoms. Journal of Dairy Research 2016;83:256-60. [DOI: 10.1017/s0022029916000066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
82 Holmes RD, Tiwari AK, Kennedy JL. Mechanisms of the placebo effect in pain and psychiatric disorders. Pharmacogenomics J 2016;16:491-500. [PMID: 27001122 DOI: 10.1038/tpj.2016.15] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
83 Thijssen AY, Clemens CH, Vankerckhoven V, Goossens H, Jonkers DM, Masclee AA. Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2016;28:8-14. [PMID: 26469356 DOI: 10.1097/MEG.0000000000000484] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
84 Giacchi V, Sciacca P, Betta P. Multistrain Probiotics. Probiotics, Prebiotics, and Synbiotics 2016. [DOI: 10.1016/b978-0-12-802189-7.00019-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Weimer K, Colloca L, Enck P. Age and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicine. Gerontology 2015;61:97-108. [PMID: 25427869 DOI: 10.1159/000365248] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
86 Khan A, Brown WA. Antidepressants versus placebo in major depression: an overview. World Psychiatry 2015;14:294-300. [PMID: 26407778 DOI: 10.1002/wps.20241] [Cited by in Crossref: 108] [Cited by in F6Publishing: 110] [Article Influence: 13.5] [Reference Citation Analysis]
87 Hou X, Chen S, Zhang Y, Sha W, Yu X, Elsawah H, Afifi AF, El-Khayat HR, Nouh A, Hassan MF, Fatah AA, Rucker Joerg I, Sánchez Núñez JM, Osthoff Rueda R, Jurkowska G, Walczak M, Malecka-Panas E, Linke K, Hartleb M, Janssen-van Solingen G. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig 2014;34:783-93. [PMID: 25258162 DOI: 10.1007/s40261-014-0233-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
88 Barboza JL, Talley NJ, Moshiree B. Current and emerging pharmacotherapeutic options for irritable bowel syndrome. Drugs 2014;74:1849-70. [PMID: 25260888 DOI: 10.1007/s40265-014-0292-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
89 Elsenbruch S, Enck P. Placebo effects and their determinants in gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2015;12:472-85. [PMID: 26194942 DOI: 10.1038/nrgastro.2015.117] [Cited by in Crossref: 109] [Cited by in F6Publishing: 86] [Article Influence: 13.6] [Reference Citation Analysis]
90 Curie A, Yang K, Kirsch I, Gollub RL, des Portes V, Kaptchuk TJ, Jensen KB. Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis. PLoS One 2015;10:e0133316. [PMID: 26226597 DOI: 10.1371/journal.pone.0133316] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
91 Peters SL, Muir JG, Gibson PR. Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:1104-15. [PMID: 25858661 DOI: 10.1111/apt.13202] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
92 Freeman R, Emir B, Parsons B. Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials. J Pain Res 2015;8:257-68. [PMID: 26082659 DOI: 10.2147/JPR.S78303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
93 Hall KT, Loscalzo J, Kaptchuk TJ. Genetics and the placebo effect: the placebome. Trends Mol Med 2015;21:285-94. [PMID: 25883069 DOI: 10.1016/j.molmed.2015.02.009] [Cited by in Crossref: 158] [Cited by in F6Publishing: 121] [Article Influence: 19.8] [Reference Citation Analysis]
94 Elsenbruch S. How positive and negative expectations shape the experience of visceral pain. Handb Exp Pharmacol 2014;225:97-119. [PMID: 25304528 DOI: 10.1007/978-3-662-44519-8_6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
95 Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis 2015;47:119-24. [PMID: 25488056 DOI: 10.1016/j.dld.2014.11.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 8.6] [Reference Citation Analysis]
96 Fukudo S, Kaneko H, Akiho H, Inamori M, Endo Y, Okumura T, Kanazawa M, Kamiya T, Sato K, Chiba T, Furuta K, Yamato S, Arakawa T, Fujiyama Y, Azuma T, Fujimoto K, Mine T, Miura S, Kinoshita Y, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50:11-30. [PMID: 25500976 DOI: 10.1007/s00535-014-1017-0] [Cited by in Crossref: 85] [Cited by in F6Publishing: 85] [Article Influence: 9.4] [Reference Citation Analysis]
97 Korterink JJ, Rutten JM, Venmans L, Benninga MA, Tabbers MM. Pharmacologic treatment in pediatric functional abdominal pain disorders: a systematic review. J Pediatr. 2015;166:424-431.e6. [PMID: 25449223 DOI: 10.1016/j.jpeds.2014.09.067] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
98 Soares RL. Irritable bowel syndrome: A clinical review. World J Gastroenterol 2014; 20(34): 12144-12160 [PMID: 25232249 DOI: 10.3748/wjg.v20.i34.12144] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 118] [Article Influence: 11.8] [Reference Citation Analysis]
99 Berrill JW, Sadlier M, Hood K, Green JT. Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. J Crohns Colitis 2014;8:945-55. [PMID: 24529603 DOI: 10.1016/j.crohns.2014.01.018] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
100 Teixeira MZ, Guedes CH, Barreto PV, Martins MA. El efecto placebo y la homeopatía1. Revista Médica de Homeopatía 2014;7:119-130. [DOI: 10.1016/j.homeo.2014.10.004] [Reference Citation Analysis]
101 Sugarman MA, Loree AM, Baltes BB, Grekin ER, Kirsch I. The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales. PLoS One 2014;9:e106337. [PMID: 25162656 DOI: 10.1371/journal.pone.0106337] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
102 Bishop FL, Aizlewood L, Adams AE. When and why placebo-prescribing is acceptable and unacceptable: a focus group study of patients' views. PLoS One 2014;9:e101822. [PMID: 25006673 DOI: 10.1371/journal.pone.0101822] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
103 Shah E, Pimentel M. Placebo effect in clinical trial design for irritable bowel syndrome. J Neurogastroenterol Motil. 2014;20:163-170. [PMID: 24840369 DOI: 10.5056/jnm.2014.20.2.163] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
104 Ludidi S, Jonkers DM, Koning CJ, Kruimel JW, Mulder L, van der Vaart IB, Conchillo JM, Masclee AA. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil 2014;26:705-14. [PMID: 24588932 DOI: 10.1111/nmo.12320] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
105 Bishop FL, Howick J, Heneghan C, Stevens S, Hobbs FD, Lewith G. Placebo use in the UK: a qualitative study exploring GPs' views on placebo effects in clinical practice. Fam Pract 2014;31:357-63. [PMID: 24736295 DOI: 10.1093/fampra/cmu016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
106 van Tilburg MA, Palsson OS, Ringel Y, Whitehead WE. Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. Complement Ther Med 2014;22:17-20. [PMID: 24559811 DOI: 10.1016/j.ctim.2013.12.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
107 Emmanuel AV. Functional problems and their medical management. Colorectal Surgery 2014. [DOI: 10.1016/b978-0-7020-4965-1.00013-5] [Reference Citation Analysis]
108 Wang X, Feng Y, Li J, Tian Z, Wei D, Qi L, Fang L, Wu K. Routine clinical administration of 4-week alverine citrate and simeticone combination relief global IBS symptoms. OJGas 2014;04:32-39. [DOI: 10.4236/ojgas.2014.41006] [Reference Citation Analysis]
109 Yoon JY, Park SJ, Cheon JH. Effect of Colostrum on the Symptoms and Mucosal Permeability in Patients with Irritable Bowel Syndrome: A Randomized Placebo-controlled Study. Intest Res 2014;12:80. [DOI: 10.5217/ir.2014.12.1.80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Brown K, Molcan E, Rajendiran E, Nusrat A, Baker J, Ruscheinsky S, Gibson DL. Free Radicals and Gastrointestinal Disorders. Systems Biology of Free Radicals and Antioxidants 2014. [DOI: 10.1007/978-3-642-30018-9_137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 Załęski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome. Prz Gastroenterol 2013;8:350-3. [PMID: 24868283 DOI: 10.5114/pg.2013.39917] [Cited by in Crossref: 12] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
112 Tfelt-hansen PC, Hougaard A. Differential effects of placebos in migraine clinical trials. Nat Rev Neurol 2014;10:10-1. [DOI: 10.1038/nrneurol.2013.255] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
113 Campagnolo AM, Priston J, Thoen RH, Medeiros T, Assunção AR. Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol 2014;18:184-91. [PMID: 25992088 DOI: 10.1055/s-0033-1352504] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
114 Sanderson C, Hardy J, Spruyt O, Currow DC. Placebo and Nocebo Effects in Randomized Controlled Trials: The Implications for Research and Practice. Journal of Pain and Symptom Management 2013;46:722-30. [DOI: 10.1016/j.jpainsymman.2012.12.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
115 Read N, Rampersad-smith L. Treating IBS in practice: a new aspect of care. Practice Nursing 2013;24:538-42. [DOI: 10.12968/pnur.2013.24.11.538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
116 Kuten-shorrer M, Kelley J, Sonis S, Treister N. Placebo effect in burning mouth syndrome: a systematic review. Oral Dis 2014;20:e1-6. [DOI: 10.1111/odi.12192] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
117 Kaplan A, Franzen MD, Nickell PV, Ransom D, Lebovitz PJ. An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. Int J Psychiatry Clin Pract 2014;18:11-5. [PMID: 23980534 DOI: 10.3109/13651501.2013.838632] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
118 Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol 2013;11:1084-1092.e3; quiz e68. [PMID: 23644388 DOI: 10.1016/j.cgh.2013.04.032] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
119 Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013;145:329-38.e1. [PMID: 23583433 DOI: 10.1053/j.gastro.2013.04.006] [Cited by in Crossref: 99] [Cited by in F6Publishing: 109] [Article Influence: 9.9] [Reference Citation Analysis]
120 Ates F, Vaezi MF. Approach to the patient with presumed extraoesophageal GERD. Best Pract Res Clin Gastroenterol 2013;27:415-31. [PMID: 23998979 DOI: 10.1016/j.bpg.2013.06.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
121 Törnblom H, Simrén M. Sequencing the Treatments. Irritable Bowel Syndrome 2013. [DOI: 10.1002/9781118444689.ch14] [Reference Citation Analysis]
122 Hom C, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease. Gastroenterol Clin North Am 2013;42:71-91. [PMID: 23452632 DOI: 10.1016/j.gtc.2012.11.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
123 Bradford A. Listening to Placebo in Clinical Trials for Female Sexual Dysfunction. The Journal of Sexual Medicine 2013;10:451-9. [DOI: 10.1111/j.1743-6109.2012.02941.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
124 Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, Conboy LA, Kelley JM, Kokkotou E, Kaptchuk TJ. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One. 2012;7:e48135. [PMID: 23110189 DOI: 10.1371/journal.pone.0048135] [Cited by in Crossref: 148] [Cited by in F6Publishing: 151] [Article Influence: 13.5] [Reference Citation Analysis]
125 Zinner NR, Ammann LP, Haas GP, Janning SW, He W, Bukofzer S. Finding unrecognized information in overactive bladder clinical trial data: a new approach to understanding placebo and treatment effects. Neurourol Urodyn 2013;32:308-13. [PMID: 23001509 DOI: 10.1002/nau.22313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
126 Rogers NJ, Mousa SA. The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. J Altern Complement Med. 2012;18:112-119. [PMID: 22339099 DOI: 10.1089/acm.2011.0015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
127 Bishop FL, Adams AE, Kaptchuk TJ, Lewith GT. Informed consent and placebo effects: a content analysis of information leaflets to identify what clinical trial participants are told about placebos. PLoS One 2012;7:e39661. [PMID: 22761859 DOI: 10.1371/journal.pone.0039661] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
128 Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother. 2012;13:433-440. [PMID: 22251066 DOI: 10.1517/14656566.2012.651458] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
129 Weimer K, Horing B, Klosterhalfen S, Enck P. [Placebo response: in studies on pain and under other clinical conditions]. Schmerz 2011;25:325-35. [PMID: 21692009 DOI: 10.1007/s00482-010-1012-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
130 Allison M. Reinventing clinical trials. Nat Biotechnol 2012;30:41-9. [DOI: 10.1038/nbt.2083] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 5.7] [Reference Citation Analysis]
131 Macedo A, Baños J, Farré M. Placebo response in the prophylaxis of migraine: A meta-analysis. European Journal of Pain 2008;12:68-75. [DOI: 10.1016/j.ejpain.2007.03.002] [Cited by in Crossref: 90] [Cited by in F6Publishing: 91] [Article Influence: 8.2] [Reference Citation Analysis]
132 Enck P, Horing B, Weimer K, Klosterhalfen S. Placebo responses and placebo effects in functional bowel disorders. Eur J Gastroenterol Hepatol 2012;24:1-8. [PMID: 21915059 DOI: 10.1097/MEG.0b013e32834bb951] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
133 Smith RE, Crone W. Is rifaximin an effective treatment option for irritable bowel syndrome? Journal of the American Academy of Physician Assistants 2011;24:E5-E6. [DOI: 10.1097/01720610-201112000-00017] [Reference Citation Analysis]
134 Abou-Ismail A, Vaezi MF. Evaluation of patients with suspected laryngopharyngeal reflux: a practical approach. Curr Gastroenterol Rep. 2011;13:213-218. [PMID: 21360069 DOI: 10.1007/s11894-011-0184-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
135 Enck P, Klosterhalfen S, Weimer K, Horing B, Zipfel S. The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci 2011;366:1889-95. [PMID: 21576146 DOI: 10.1098/rstb.2010.0384] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 8.8] [Reference Citation Analysis]
136 Layer P, Keller J, Loeffler H, Kreiss A. Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. Ther Clin Risk Manag 2007;3:107-18. [PMID: 18360619 DOI: 10.2147/tcrm.2007.3.1.107] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
137 Enck P, Klosterhalfen S, Zipfel S. Novel study designs to investigate the placebo response. BMC Med Res Methodol 2011;11:90. [PMID: 21663609 DOI: 10.1186/1471-2288-11-90] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
138 Baudon J. Colopathies de l’adolescent. Journal de Pédiatrie et de Puériculture 2011;24:145-151. [DOI: 10.1016/j.jpp.2011.03.014] [Reference Citation Analysis]
139 Koog YH, We SR, Min BI. Three-armed trials including placebo and no-treatment groups may be subject to publication bias: systematic review. PLoS One 2011;6:e20679. [PMID: 21655196 DOI: 10.1371/journal.pone.0020679] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
140 Tanaka Y, Kanazawa M, Fukudo S, Drossman DA. Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17:131-139. [PMID: 21602989 DOI: 10.5056/jnm.2011.17.2.13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
141 Tanaka Y, Kanazawa M, Fukudo S, Drossman DA. Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17:131-139. [PMID: 21602989 DOI: 10.5056/jnm.2011.17.2.131] [Cited by in Crossref: 172] [Cited by in F6Publishing: 182] [Article Influence: 14.3] [Reference Citation Analysis]
142 . References. The Philosophy of Evidence‐Based Medicine 2011. [DOI: 10.1002/9781444342673.refs] [Reference Citation Analysis]
143 Lu CL, Chang FY. Placebo effect in patients with irritable bowel syndrome. J Gastroenterol Hepatol 2011;26 Suppl 3:116-8. [PMID: 21751434 DOI: 10.1111/j.1440-1746.2011.06651.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
144 Jackson JL, Damm TW. Barriers to the use of tricyclic antidepressants in the management of pain. Pain Management 2011;1:99-101. [DOI: 10.2217/pmt.11.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Chapman CM, Gibson GR, Rowland I. Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr. 2011;50:1-17. [PMID: 21229254 DOI: 10.1007/s00394-010-0166-z] [Cited by in Crossref: 275] [Cited by in F6Publishing: 229] [Article Influence: 22.9] [Reference Citation Analysis]
146 Baudon J. Colopatías de la adolescencia. EMC - Pediatría 2011;46:1-6. [DOI: 10.1016/s1245-1789(11)70999-4] [Reference Citation Analysis]
147 Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010;5:e15591. [PMID: 21203519 DOI: 10.1371/journal.pone.0015591] [Cited by in Crossref: 522] [Cited by in F6Publishing: 555] [Article Influence: 40.2] [Reference Citation Analysis]
148 Ljótsson B, Andréewitch S, Hedman E, Rück C, Andersson G, Lindefors N. Exposure and mindfulness based therapy for irritable bowel syndrome – An open pilot study. Journal of Behavior Therapy and Experimental Psychiatry 2010;41:185-90. [DOI: 10.1016/j.jbtep.2010.01.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
149 Teixeira MZ, Guedes CH, Barreto PV, Martins MA. The placebo effect and homeopathy. Homeopathy. 2010;99:119-129. [PMID: 20471615 DOI: 10.1016/j.homp.2010.02.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
150 Cremonini F, Ziogas DC, Chang HY, Kokkotou E, Kelley JM, Conboy L, Kaptchuk TJ, Lembo AJ. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010;32:29-42. [PMID: 20353496 DOI: 10.1111/j.1365-2036.2010.04315.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
151 Guandalini S, Magazzù G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, Sibal A, Romano C, Canani RB, Lionetti P, Setty M. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 2010;51:24-30. [PMID: 20453678 DOI: 10.1097/MPG.0b013e3181ca4d95] [Cited by in Crossref: 177] [Cited by in F6Publishing: 169] [Article Influence: 13.6] [Reference Citation Analysis]
152 Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-58. [PMID: 20412064 DOI: 10.1111/j.1365-2036.2010.04328.x] [Cited by in Crossref: 151] [Cited by in F6Publishing: 134] [Article Influence: 11.6] [Reference Citation Analysis]
153 Enck P, Klosterhalfen S, Zipfel S. Acupuncture, psyche and the placebo response. Auton Neurosci. 2010;157:68-73. [PMID: 20359961 DOI: 10.1016/j.autneu.2010.03.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
154 Rao SS, Valestin J, Brown CK, Zimmerman B, Schulze K. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am J Gastroenterol 2010;105:890-6. [PMID: 20179692 DOI: 10.1038/ajg.2010.53] [Cited by in Crossref: 143] [Cited by in F6Publishing: 140] [Article Influence: 11.0] [Reference Citation Analysis]
155 Ljótsson B, Falk L, Vesterlund AW, Hedman E, Lindfors P, Rück C, Hursti T, Andréewitch S, Jansson L, Lindefors N. Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome--a randomized controlled trial. Behav Res Ther. 2010;48:531-539. [PMID: 20362976 DOI: 10.1016/j.brat.2010.03.003] [Cited by in Crossref: 169] [Cited by in F6Publishing: 179] [Article Influence: 13.0] [Reference Citation Analysis]
156 Jia G, Meng MB, Huang ZW, Qing X, Lei W, Yang XN, Liu SS, Diao JC, Hu SY, Lin BH, Zhang RM. Treatment of functional constipation with the Yun-chang capsule: a double-blind, randomized, placebo-controlled, dose-escalation trial. J Gastroenterol Hepatol 2010;25:487-93. [PMID: 20370727 DOI: 10.1111/j.1440-1746.2009.06189.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
157 Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16(5): 547-553 [PMID: 20128021 DOI: 10.3748/wjg.v16.i5.547] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 57] [Article Influence: 3.3] [Reference Citation Analysis]
158 Duracinsky M, Chassany O. [How can an effective drug to treat irritable bowel syndrome be successfully developed?]. Gastroenterol Clin Biol 2009;33 Suppl 1:S26-34. [PMID: 19303535 DOI: 10.1016/S0399-8320(09)71522-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
159 Baudon J. Colopathies de l'adolescent. EMC - Pédiatrie - Maladies infectieuses 2010;5:1-6. [DOI: 10.1016/s1637-5017(10)72472-8] [Reference Citation Analysis]
160 Bruley des Varannes S. [Irritable bowel syndrome: outcome aspects]. Gastroenterol Clin Biol 2009;33 Suppl 1:S84-90. [PMID: 19303543 DOI: 10.1016/S0399-8320(09)71529-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
161 Kaptchuk TJ, Shaw J, Kerr CE, Conboy LA, Kelley JM, Csordas TJ, Lembo AJ, Jacobson EE. "Maybe I made up the whole thing": placebos and patients' experiences in a randomized controlled trial. Cult Med Psychiatry 2009;33:382-411. [PMID: 19597976 DOI: 10.1007/s11013-009-9141-7] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 7.2] [Reference Citation Analysis]
162 Hughes C, Smyth S, Lowe-strong A. Reflexology for the treatment of pain in people with multiple sclerosis: a double-blind randomised sham-controlled clinical trial. Mult Scler 2009;15:1329-38. [DOI: 10.1177/1352458509345916] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
163 Walach H, Schneider R. Does the presence of a pharmacological substance alter the placebo effect?-results of two experimental studies using the placebo-caffeine paradigm. Hum Psychopharmacol Clin Exp 2009;24:549-58. [DOI: 10.1002/hup.1054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
164 Benninga MA, Mayer EA. The power of placebo in pediatric functional gastrointestinal disease. Gastroenterology 2009;137:1207-10. [PMID: 19717127 DOI: 10.1053/j.gastro.2009.08.023] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
165 Saps M, Youssef N, Miranda A, Nurko S, Hyman P, Cocjin J, Di Lorenzo C. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009;137:1261-9. [PMID: 19596010 DOI: 10.1053/j.gastro.2009.06.060] [Cited by in Crossref: 169] [Cited by in F6Publishing: 178] [Article Influence: 12.1] [Reference Citation Analysis]
166 Brennan BP, Fogarty KV, Roberts JL, Reynolds KA, Pope HG, Hudson JI. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol. 2009;24:423-428. [PMID: 19548294 DOI: 10.1002/hup.1038] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 4.6] [Reference Citation Analysis]
167 Howick J. Questioning the methodologic superiority of 'placebo' over 'active' controlled trials. Am J Bioeth 2009;9:34-48. [PMID: 19998192 DOI: 10.1080/15265160903090041] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
168 Meissner K. Effects of placebo interventions on gastric motility and general autonomic activity. J Psychosom Res 2009;66:391-8. [PMID: 19379955 DOI: 10.1016/j.jpsychores.2008.09.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
169 Hong KS, Kang HW, Im JP, Ji GE, Kim SG, Jung HC, Song IS, Kim JS. Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut Liver 2009;3:101-7. [PMID: 20431731 DOI: 10.5009/gnl.2009.3.2.101] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 3.6] [Reference Citation Analysis]
170 Enck P, Zipfel S, Klosterhalfen S. Der Placeboeffekt in der Medizin. Bundesgesundheitsbl 2009;52:635-42. [DOI: 10.1007/s00103-009-0849-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
171 Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121:119-124. [PMID: 19332970 DOI: 10.3810/pgm.2009.03.1984] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 5.1] [Reference Citation Analysis]
172 Enck P, Vinson B, Malfertheiner P, Zipfel S, Klosterhalfen S. The placebo response in functional dyspepsia--reanalysis of trial data. Neurogastroenterol Motil 2009;21:370-7. [PMID: 19210629 DOI: 10.1111/j.1365-2982.2008.01241.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
173 Klosterhalfen S, Kellermann S, Braun S, Kowalski A, Schrauth M, Zipfel S, Enck P. Gender and the nocebo response following conditioning and expectancy. Journal of Psychosomatic Research 2009;66:323-8. [DOI: 10.1016/j.jpsychores.2008.09.019] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 4.6] [Reference Citation Analysis]
174 Stacher G. Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome? Expert Rev Gastroenterol Hepatol 2007;1:15-27. [PMID: 19072430 DOI: 10.1586/17474124.1.1.15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
175 Pickett-blakely O, Lee L. Irritable Bowel Syndrome. Food and Nutrients in Disease Management 2009. [DOI: 10.1201/9781420067637.ch13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
176 Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41. [PMID: 19006537 DOI: 10.1111/j.1365-2036.2008.03881.x] [Cited by in Crossref: 277] [Cited by in F6Publishing: 249] [Article Influence: 19.8] [Reference Citation Analysis]
177 Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, Corfe BM. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009;29:97-103. [PMID: 18785988 DOI: 10.1111/j.1365-2036.2008.03848.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 6.1] [Reference Citation Analysis]
178 Hellström PM, Hein J, Bytzer P, Björnssön E, Kristensen J, Schambye H. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009;29:198-206. [PMID: 18945254 DOI: 10.1111/j.1365-2036.2008.03870.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 4.5] [Reference Citation Analysis]
179 Frye JW, Vaezi MF. Extraesophageal GERD. Gastroenterol Clin North Am 2008;37:845-58, ix. [PMID: 19028321 DOI: 10.1016/j.gtc.2008.09.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
180 Spiller RC, Meyers NL, Hickling RI. Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial. Dig Dis Sci 2008;53:3191-200. [PMID: 18465239 DOI: 10.1007/s10620-008-0295-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
181 Scarpellini E, Tack J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opinion on Investigational Drugs 2008;17:1663-70. [DOI: 10.1517/13543784.17.11.1663] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
182 Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. Neuron 2008;59:195-206. [PMID: 18667148 DOI: 10.1016/j.neuron.2008.06.030] [Cited by in Crossref: 391] [Cited by in F6Publishing: 320] [Article Influence: 26.1] [Reference Citation Analysis]
183 Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:385-96. [PMID: 18532993 DOI: 10.1111/j.1365-2036.2008.03750.x] [Cited by in Crossref: 118] [Cited by in F6Publishing: 120] [Article Influence: 7.9] [Reference Citation Analysis]
184 Jarcho JM, Chang L, Berman M, Suyenobu B, Naliboff BD, Lieberman MD, Ameen VZ, Mandelkern MA, Mayer EA. Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study. Aliment Pharmacol Ther 2008;28:344-52. [PMID: 19086332 DOI: 10.1111/j.1365-2036.2008.03721.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
185 Reynolds JA, Bland JM, MacPherson H. Acupuncture for irritable bowel syndrome an exploratory randomised controlled trial. Acupunct Med. 2008;26:8-16. [PMID: 18356794 DOI: 10.1136/aim.26.1.8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
186 Klosterhalfen S, Enck P. Neurophysiology and psychobiology of the placebo response. Curr Opin Psychiatry 2008;21:189-95. [PMID: 18332669 DOI: 10.1097/YCO.0b013e3282f50c36] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
187 George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther 2008;27:830-7. [PMID: 18284648 DOI: 10.1111/j.1365-2036.2008.03649.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
188 Chang L. The trials and tribulations of drug development for functional gastrointestinal disorders. Neurogastroenterol Motil 2008;20 Suppl 1:130-8. [PMID: 18402650 DOI: 10.1111/j.1365-2982.2008.01093.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
189 Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, Kirsch I, Schyner RN, Nam BH, Nguyen LT. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008;336:999-1003. [PMID: 18390493 DOI: 10.1136/bmj.39524.439618.25] [Cited by in Crossref: 806] [Cited by in F6Publishing: 836] [Article Influence: 53.7] [Reference Citation Analysis]
190 Heiman DL, Lishnak TS, Trojian TH. Irritable Bowel Syndrome in Athletes and Exercise: . Current Sports Medicine Reports 2008;7:100-3. [DOI: 10.1097/01.csmr.0000313396.10064.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
191 Shi J, Tong Y, Shen JG, Li HX. Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: A systematic review. World J Gastroenterol 2008; 14(3): 454-462 [PMID: 18200670 DOI: 10.3748/wjg.14.454] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
192 Moser G. Psychosomatische Aspekte der funktionellen gastrointestinalen Störungen. Psychosomatik in der Gastroenterologie und Hepatologie. [DOI: 10.1007/978-3-211-69159-5_5] [Reference Citation Analysis]
193 Enck P, Klosterhalfen S. Placebo-Wirkungen bei Magen-Darm-Erkrankungen. Psychosomatik in der Gastroenterologie und Hepatologie. [DOI: 10.1007/978-3-211-69159-5_9] [Reference Citation Analysis]
194 Vlieger AM, Menko-Frankenhuis C, Wolfkamp SC, Tromp E, Benninga MA. Hypnotherapy for children with functional abdominal pain or irritable bowel syndrome: a randomized controlled trial. Gastroenterology 2007;133:1430-6. [PMID: 17919634 DOI: 10.1053/j.gastro.2007.08.072] [Cited by in Crossref: 209] [Cited by in F6Publishing: 215] [Article Influence: 13.1] [Reference Citation Analysis]
195 Duracinsky M, Chassany O. Syndrome de l’intestin irritable : pourquoi est-il si difficile de trouver un traitement efficace ? Colon Rectum 2007;1:248-254. [DOI: 10.1007/s11725-007-0059-3] [Reference Citation Analysis]
196 Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2007;22:1183-9. [PMID: 17688659 DOI: 10.1111/j.1440-1746.2006.04543.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
197 Musial F, Klosterhalfen S, Enck P. Placebo responses in patients with gastrointestinal disorders. World J Gastroenterol 2007; 13(25): 3425-3429 [PMID: 17659688 DOI: 10.3748/wjg.v13.i25.3425] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
198 Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007;25:1271-81. [PMID: 17509095 DOI: 10.1111/j.1365-2036.2007.03313.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
199 Chassany O, Bonaz B, Bruley DES Varannes S, Bueno L, Cargill G, Coffin B, Ducrotté P, Grangé V. Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2007;25:1115-23. [PMID: 17439513 DOI: 10.1111/j.1365-2036.2007.03296.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
200 Rao SS, Mudipalli RS, Remes-Troche JM, Utech CL, Zimmerman B. Theophylline improves esophageal chest pain--a randomized, placebo-controlled study. Am J Gastroenterol 2007;102:930-8. [PMID: 17313494 DOI: 10.1111/j.1572-0241.2007.01112.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
201 Rao SS, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, Zimmerman B, Schulze K. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 2007;5:331-8. [PMID: 17368232 DOI: 10.1016/j.cgh.2006.12.023] [Cited by in Crossref: 262] [Cited by in F6Publishing: 201] [Article Influence: 16.4] [Reference Citation Analysis]
202 Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007;132:516-26. [PMID: 17258720 DOI: 10.1053/j.gastro.2006.12.037] [Cited by in Crossref: 110] [Cited by in F6Publishing: 114] [Article Influence: 6.9] [Reference Citation Analysis]
203 Hicks G. Irritable Bowel Syndrome. Comprehensive Medicinal Chemistry II 2007. [DOI: 10.1016/b0-08-045044-x/00283-2] [Reference Citation Analysis]
204 Enck P, Kowalski A, Martens U, Klosterhalfen S. Internet-based assessment of bowel symptoms and quality of life. Eur J Gastroenterol Hepatol 2006;18:1263-9. [PMID: 17099374 DOI: 10.1097/01.meg.0000243879.25067.32] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
205 Qadeer MA, Phillips CO, Lopez AR, Steward DL, Noordzij JP, Wo JM, Suurna M, Havas T, Howden CW, Vaezi MF. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006;101:2646-54. [PMID: 17037995 DOI: 10.1111/j.1572-0241.2006.00844.x] [Cited by in Crossref: 208] [Cited by in F6Publishing: 198] [Article Influence: 12.2] [Reference Citation Analysis]
206 Olden KW. REVIEW OF ACUPUNCTURE TREATMENT IN IRRITABLE BOWEL SYNDROME. Evidence-Based Gastroenterology 2006;7:102-103. [DOI: 10.1097/01.ebg.0000211628.76691.05] [Reference Citation Analysis]
207 Talley NJ. Irritable bowel syndrome. Intern Med J 2006;36:724-8. [PMID: 17040359 DOI: 10.1111/j.1445-5994.2006.01217.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 3.6] [Reference Citation Analysis]
208 van Leeuwen JHS, Castro R, Busse M, Bemelmans BL. The Placebo Effect in the Pharmacologic Treatment of Patients with Lower Urinary Tract Symptoms. European Urology 2006;50:440-53. [DOI: 10.1016/j.eururo.2006.05.014] [Cited by in Crossref: 107] [Cited by in F6Publishing: 109] [Article Influence: 6.3] [Reference Citation Analysis]
209 Pacheco-López G, Engler H, Niemi MB, Schedlowski M. Expectations and associations that heal: Immunomodulatory placebo effects and its neurobiology. Brain Behav Immun 2006;20:430-46. [PMID: 16887325 DOI: 10.1016/j.bbi.2006.05.003] [Cited by in Crossref: 112] [Cited by in F6Publishing: 117] [Article Influence: 6.6] [Reference Citation Analysis]
210 Young P, Cash BD. Probiotic use in irritable bowel syndrome. Curr Gastroenterol Rep 2006;8:321-6. [DOI: 10.1007/s11894-006-0053-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
211 Schneider A, Enck P, Streitberger K, Weiland C, Bagheri S, Witte S, Friederich HC, Herzog W, Zipfel S. Acupuncture treatment in irritable bowel syndrome. Gut 2006;55:649-54. [PMID: 16150852 DOI: 10.1136/gut.2005.074518] [Cited by in Crossref: 99] [Cited by in F6Publishing: 98] [Article Influence: 5.8] [Reference Citation Analysis]
212 Hungin AP. Self-help interventions in irritable bowel syndrome. Gut 2006;55:603-4. [PMID: 16609132 DOI: 10.1136/gut.2005.075606] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
213 Su C. Outcomes of placebo therapy in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:328-33. [PMID: 16633054 DOI: 10.1097/01.MIB.0000215094.69869.2e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
214 Gilkin RJ. The spectrum of irritable bowel syndrome: A clinical review. Clin Ther. 2005;27:1696-1709. [PMID: 16368443 DOI: 10.1016/j.clinthera.2005.11.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
215 Hussain Z, Quigley EM. Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:465-71. [PMID: 16441466 DOI: 10.1111/j.1365-2036.2006.02776.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 4.5] [Reference Citation Analysis]
216 Conboy LA, Wasserman RH, Jacobson EE, Davis RB, Legedza AT, Park M, Rivers AL, Morey EB, Nam BH, Lasagna L, Kirsch I, Lembo AJ, Kaptchuk TJ, Kerr CE. Investigating placebo effects in irritable bowel syndrome: a novel research design. Contemp Clin Trials 2006;27:123-34. [PMID: 16427366 DOI: 10.1016/j.cct.2005.11.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
217 Cho HJ. Reviving the old sermon of medicine with the placebo effect. Rev Bras Psiquiatr 2005;27:336-40. [DOI: 10.1590/s1516-44462005000400015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
218 Enck P, Klosterhalfen S, Kruis W. Factors affecting therapeutic placebo response rates in patients with irritable bowel syndrome. Nat Rev Gastroenterol Hepatol 2005;2:354-5. [DOI: 10.1038/ncpgasthep0237] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]